News & Updates

The use of mitapivat increased haemoglobin (Hb) levels in patients with pyruvate kinase deficiency (PKD) who did not receive any regular blood transfusions, according to the ACTIVATE* study.

Taking P2B001, a novel polypill comprising fixed-dose combination of 0.6 mg pramipexole (PPX) and 0.75 mg of rasagiline (RAS), was better than taking either drug component alone for symptomatic control of Parkinson’s disease, according to results of a late-breaking phase III study presented at AAN 2022.

Using the antifibrinolytic tranexamic acid (TXA) during noncardiac surgery significantly reduces bleeding without significant increases in vascular complications in patients at risk for these complications, according to the POISE-3* trial presented at ACC 2022.

The humanized IgG4 monoclonal antibody tislelizumab was clinically active in women with gynaecologic microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) solid tumours, and was generally well-tolerated with no new safety signals, according to a subgroup analysis of the phase II RATIONALE 209 study presented at SGO 2022.

In the treatment of patients with uveitis, adalimumab delivers long-term efficacy while having an acceptable side-effect profile, according to real-world data.